About Kurt Harrington
Kurt Harrington is founder and chief executive officer of Ventoux Biosciences, which develops treatments for Dupuytren’s disease. A patient with Dupuytren’s and Ledderhose disease, he formed the company to address the limited treatment options for Dupuytren’s.
Harrington has more than 25 years of biopharmaceutical experience. Before Ventoux, he advised company leaders on commercialization, strategy and business development. His work also covered market access and product development. He previously held roles at AstraZeneca and Biogen. He also worked at Amylin, Cadence Pharmaceuticals and Avanir. He earned an M.B.A. in pharmaceutical marketing from Saint Joseph’s University and a B.S. in marketing from Western Michigan University. He is also a director of Ventoux.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Kurt Harrington in the role, so the role may have started earlier or lasted longer.
